Middle East Journal of Cancer، جلد ۶، شماره ۳، صفحات ۱۷۱-۰
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Hematologic Toxicities in Colorectal Cancer Patients who Received FOLFOX4
چکیده انگلیسی مقاله Background: Over the past decade, survival from advanced colorectal cancer is increasing. Therefore patients have more exposure to chemotherapy and related toxicities. This study determines how hematologic toxicity patterns affect therapy and care. Methods: From April 2010 to March 2013, we enrolled 127 patients with stages IIb to IV colorectal cancer. Patients underwent complete blood count monitoring prior to and during each cycle of FOLFOX4 chemotherapy. Granulocyte colony stimulating factor was injected if their white blood cells were below 3.5×109/L. Results: The most common hematologic toxicities were grades 1-2 for hemoglobin (76.83%) and leukopenia (26.48%). The least common hematologic toxicity was thrombocytopenia (4.69%) for all grades of platelet toxicity. The median granulocyte colony stimulating factor injection was 3.33 per 12 cycles. Conclusion: Anemia and leukopenia are the most common hematologic abnormalities expected with FOLFOX4 chemotherapy regimens for colorectal cancer. The most important factor for predicting hematologic toxicities in patients who receive chemotherapy for colorectal cancer is the number of chemotherapy cycles.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله مهدی دهقانی | mehdi dehghani
department of hematology and oncology, hematology research center, shiraz university of medical sciences, shiraz, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (Shiraz university of medical sciences)

نعمت اله حافظی | nematollah hafezi
department of hematology and oncology, hematology research center, shiraz university of medical sciences, shiraz, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (Shiraz university of medical sciences)

رضا وجدانی | reza vojdani
department of hematology and oncology, hematology research center, shiraz university of medical sciences, shiraz, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (Shiraz university of medical sciences)

مانی رمزی | mani ramzi
department of hematology and oncology, hematology research center, shiraz university of medical sciences, shiraz, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (Shiraz university of medical sciences)

مجتبی کریمی | mojtaba karimi
department of hematology and oncology, hematology research center, shiraz university of medical sciences, shiraz, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (Shiraz university of medical sciences)

حبیب نورانی | habib nourani
department of hematology and oncology, hematology research center, shiraz university of medical sciences, shiraz, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (Shiraz university of medical sciences)

مریم ذاکری نیا | maryam zakerinia
department of hematology and oncology, hematology research center, shiraz university of medical sciences, shiraz, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (Shiraz university of medical sciences)

زهرا بهادر | zahra bahador
department of hematology and oncology, hematology research center, shiraz university of medical sciences, shiraz, iran

سازمان اصلی تایید شده: دانشگاه علوم پزشکی شیراز (Shiraz university of medical sciences)

نشانی اینترنتی http://mejc.sums.ac.ir/index.php/mejc/article/view/237
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Article
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات